Lead Indication – Plinabulin

Lead asset, Plinabulin, a novel immuno-oncology agent, is in late-stage clinical trials for the treatment of chemotherapy-induced neutropenia and advanced non-small cell lung cancer (NSCLC).

Learn More

Dual-market US/China development strategy

By employing a novel, scalable business model that integrates clinical resources in the U.S. and China, BeyondSpring seeks to create maximum value for patient, physicians, payers and other stakeholders.

Learn More

Recent News

BeyondSpring is focused on providing regular updates on its clinical programs through press releases, webcasts and media interviews. To stay up to date on the Company’s announcements and featured media articles, please click the appropriate link below.

Company Announcements